General MedicationsINJECTIONGeneric
KANAMYCIN SULFATE
KANAMYCIN SULFATE
Standard Dose
EQ 500MG BASE/2ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview KANAMYCIN SULFATE is listed in Drugs@FDA under application 065111 (ANDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient KANAMYCIN SULFATE Form and strength INJECTABLE;INJECTION - EQ 500MG BASE/2ML Sponsor FRESENIUS KABI USA Submission history Latest submission status date: 2015-07-15 00:00:00.
Structured Monograph
Clinical summary
Approval overview KANAMYCIN SULFATE is listed in Drugs@FDA under application 065111 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient KANAMYCIN SULFATE Form and strength INJECTABLE;INJECTION - EQ 500MG BASE/2ML Sponsor FRESENIUS KABI USA Submission history Latest submission status date: 2015-07-15 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.